CPA
SPRY icon

Capital Performance Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Capital Performance Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33
Closed -$479 – 2330
2024
Q3 		$479 Buy
+33
New +$393 ﹤0.01% 2274

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Capital Performance Advisors's SPRY Position: Q4 2024 in Review

Capital Performance Advisors sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 33 shares — an estimated $479 sold.

Capital Performance Advisors first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $479 in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Capital Performance Advisors reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 33 ARS Pharmaceuticals shares in Q4 2024, an estimated $479.
  • Capital Performance Advisors first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's ARS Pharmaceuticals position peaked at $479 in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.